Gb Sciences Inc. (OTCMKTS:GBLX) Stock Takes a Hit After Recent News
Gb Sciences Inc. (OTCMKTS:GBLX) has co-published a study in the journal Frontiers in Pharmacology that talks about the efficacy of its proprietary cannabinoid-containing, minimum essential mixtures (MEM) for the treatment of Parkinson’s disease (PD).
Trading Data
On Monday, GBLX stock slid 9.14% to $0.0254 with 106.24K shares, compared to volume of 110.55K shares. The stock moved within a range of $0.0250 – 0.0264 after opening trade at $0.0250.
Gb Sciences Co-Publishes Study Demonstrating Efficacy of Its Proprietary Cannabinoid Mixtures for the Treatment of Parkinson’s Disease
For this Gb Sciences-sponsored study, the discovery research using cell models of Parkinson’s disease was performed at Chaminade University (Honolulu, Hawai’i, USA), and the MEM refinement and validation research was performed in a zebrafish model of Parkinson’s disease at the National Research Council of Canada (NRC). The market for Parkinson’s disease treatments is expected to surge to $8.8 billion by 2026.
The study is entitled “Identification of minimum essential therapeutic mixtures from Cannabis plant extracts by screening in cell and animal models of Parkinson’s disease”. It was co-authored by Gb Sciences’ own President and Chief Science Officer Andrea Small-Howard and her collaborators Michael G. Morash, Jessica Nixon, and Lee Ellis from the National Research Council of Canada; Lori M.N. Shimoda and Helen Turner from Chaminade University of Honolulu; and Alexander J. Stokes from the University of Hawai’i at Manoa (Manoa, Hawai’i, USA).
This paper identifies promising minimal essential mixtures of cannabinoids based on a step-wise, strategic approach to reducing the complexity of the plant secondary metabolome. The sequential use of in silico, in vitro, and medium throughput in vivo experimental systems has generated refined, de-risked mixtures that can now be tested in additional, higher-cost, preclinical model systems of PD.
Key Quote
“Our drug discovery process has identified promising ratio-controlled mixtures of cannabis-inspired compounds for the treatment of Parkinson’s disease, which have proven effective at reducing Parkinsonian motor symptoms in an animal model of the disease,” said Dr. Andrea Small Howard, President, Chief Science Officer, and Director of Gb Sciences. “This study allows us to continue addressing unmet clinical needs through the development of novel plant-inspired drugs, and positions Gb Sciences as a contributor to the expanding world of novel PD therapeutics.”
Traders Corner
GBLX stock is trading below the 50-Day and 200-Day Moving averages of $0.0269 and $0.0271 respectively. Moreover, the stock is trading below the 20-Day moving average of $0.0282.
